Salius Pharma Pvt. Ltd.
Salius Pharma Pvt. Ltd.
Send Email
0804895104960% Response Rate

Home » Company Brief » News Coverage

News Coverage

New Product Launched

New Product Launched

Supercal- DZM

Salius pharma has announced the launch of a new dietary supplement Supercal-DZM which contains Calcium Citrate Malate, the most absorbing form of Calcium with other essential minerals and vitamin D3. It is used in people with low blood calcium levels, people with weak bones, in pregnant women and nursing mothers.

Supercal DZM is a Supplement containing the Unique preparation of essential minerals and vitamins such as Calcium, Magnesium, Zinc and VitaminD3. It is given to the individuals who do not obtain these essential minerals and vitamins through their regular diet. SUPERCAL DZM is indicated in Osteoporosis, Osteomalacia /rickets, Decreased Activity of parathyroid gland hypoparathyroidism, Fracture, Spondylosis, Rheumatoid arthritis and Osteoarthritis. Calcium helps in maintaining healthy bones and teeth. Along with magnesium it regulates heart functions and conducts nerve impulses. Adequate intake of zinc maintains the vision and immune system and during pregnancy it promotes normal growth and development in their children. Vitamin D3 helps in the bone metabolism and it also exhibits anti-inflammatory and immune modulating properties. It acts as a protection barrier against bone diseases. Along with vitamin D3 the body absorbs calcium which is essential for maintaining strong bones.

Recommended dose: 1-2 tablets to be taken once daily.


Salius pharma has launched a new once-daily medication CROHIST-MK to treat Allergic Rhinitis and also used in the prevention and management of asthma.

CROHIST– MK is a combination formulation which contains the generic medications Levocetirizine Dihydrochloride and Montelukast sodium where Levocetirizine Dihydrochloride is an Anti-histaminic agent and Montelukast sodium is an Anti-asthmatic agent. CROHIST MK is available both in the Tablet and Syrup forms. Montelukast sodium is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor. Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Montelukast blocks the actions of leukotriene receptor. CROHIST MK is used for the treatment of Allergic Rhinitis (Seasonal and Perennial) and chronic treatment of Asthma. Patients those who are hypersensitive to Montelukast, Levocetirizine or to any other Piperazine derivatives and those who experience severe renal impairment are not supposed to take this medication. Concomitant treatment of patients with Montelukast sodium and Levocetirizine Dihydrochloride has proven with better results than monotherapy of Montelukast sodium and Levocetirizine Dihydrochloride since there was less potential for hepatotoxicity.

CROHIST MK is a safe, efficacious and well-tolerated drug with less sedative effects.

Recommended dose: One tablet to be taken once daily in the evening.

CMD of Salius Pharma Mr. A.K. PATRA received the award for "Emerging Pharma Leader of the Year 2013"

CMD of Salius Pharma Mr. A.K. PATRA received the award for
Chairman & CEO Mr. A. K. Patra received the award for "Emerging Pharma Leader of the Year 2013" in a glittering function held at The Hotel Hilton, Mumbai on 27th Dec. 2013.

News Headlines

Franchise Partners/ Associates / C& F Agents : We, Salius Pharma, intend to grow much faster than the industry with a broader product range and new markets. We are looking for Franchise Partners/ Associates / C& F Agents /Growth Partners from across India ,Who have Capacity to invest minimum Rs.10-15 lakhs initially with proper office set up and Storage Facility. We aim to continue to grow our Business and Deliver Superior Returns to our Shareholders through Innovative ways to make Staying Healthy ,Affordable & Accessible to as many People as Possible, Which is the defining principle of universal health care. For more details contact us.

Salius Pharma going to be launched in India in the year 2019

Salius Pharma going to be launched in India in the year 2019

Our New pharmacokinetically enhanced tablet dosage form ReclaMox(Amoxicillin / Clavulanate Potassium Tablets)Each Film-Coated Tablet Contains Amoxicillin Trihydrate equivalent to 500 mg Amoxicillin and Clavulanate Potassium equivalent to 125 mg of Clavulanic Acid.




Contact via E-mail
Contact via SMS
A. K. Patra (CMD & CEO)
Salius Pharma Pvt. Ltd.
B-704, Technocity, TTC Industrial Area, MIDC,Rabale
Navi Mumbai - 400705, Thane, Maharashtra, India
Call Us: 
Call Response Rate: 60%
Share Us :

Home  |   Company Brief   |  Products  |  Site Map  |   Contact Us

© Salius Pharma Pvt. Ltd.. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited

Salius Pharma Pvt. Ltd.